Biotech Values

[ghmm]

Danoprevir:

For what its worth Roche has actually been talking about this for some time. I recall them talking about this on at least one conference call some time ago. Someone with search could look at my posts I may have even posted about that.

I'm not much for investing in HCV (Not that this is a meaningful product for Roche) in general and I especially don't like a business model that is focused on competing on price .